CAR-T (Chimeric antigen receptor) cell therapy

CAR-T Cell Therapy represents a groundbreaking approach in the treatment of hematologic cancers, including multiple myeloma, lymphomas and leukemia, particularly for patients with refractory or relapsed forms of these diseases. This personalized therapy modifies a patient’s own T cells to target and destroy cancer cells, providing an advanced solution for those who have not responded to conventional treatments.

Ospedale San Raffaele has been at the forefront of CAR-T Cell Therapy, contributing to the development and application of innovative protocols that have greatly improved patient outcomes. As one of the first centers in Italy to adopt CAR-T Cell Therapy, it remains dedicated to research and clinical trials aimed at expanding the effectiveness of these treatments across a wider range of cancers. The center’s experts collaborate closely with national and international research networks, ensuring that patients receive care informed by the latest scientific advancements.